J S Miller

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma
    Noel Laudi
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 11:129-35. 2005
  2. ncbi request reprint Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation
    Jeffrey S Miller
    Divisions of Medical and Pediatric Hematology Oncology and Transplantation, The Blood and Marrow Transplant Program, Department of Biostatistics, and The University of Minnesota Cancer Center, MN 55455, USA
    Clin Immunol 117:144-51. 2005
  3. pmc Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells
    Bartosz Grzywacz
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, 425 E River Rd, Suite 660, Minneapolis, MN 55455, USA
    Blood 108:3824-33. 2006
  4. ncbi request reprint Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma
    M Tomblyn
    Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 40:111-8. 2007
  5. pmc Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:282-9. 2008
  6. ncbi request reprint The biology of natural killer cells in cancer, infection, and pregnancy
    J S Miller
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minn 55455, USA
    Exp Hematol 29:1157-68. 2001
  7. ncbi request reprint Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2
    J S Miller
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Blood 98:705-13. 2001
  8. ncbi request reprint Biology of natural killer cells in cancer and infection
    Jeffrey S Miller
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Box 806, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Cancer Invest 20:405-19. 2002
  9. ncbi request reprint Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells
    J S Miller
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 93:96-106. 1999
  10. ncbi request reprint Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor
    J S Miller
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis 55455, USA
    J Immunol 162:7376-82. 1999

Detail Information

Publications85

  1. ncbi request reprint Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma
    Noel Laudi
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 11:129-35. 2005
    ....
  2. ncbi request reprint Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation
    Jeffrey S Miller
    Divisions of Medical and Pediatric Hematology Oncology and Transplantation, The Blood and Marrow Transplant Program, Department of Biostatistics, and The University of Minnesota Cancer Center, MN 55455, USA
    Clin Immunol 117:144-51. 2005
    ..KLH vaccines are safe and require only a single injection to test neo-antigen responses providing an optimal platform for definitive testing of strategies to improve diminished immune recovery after chemotherapy or post-HCT...
  3. pmc Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells
    Bartosz Grzywacz
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, 425 E River Rd, Suite 660, Minneapolis, MN 55455, USA
    Blood 108:3824-33. 2006
    ..The identified stages of NK-cell differentiation provide evidence for coordinated acquisition of HLA-specific inhibitory receptors (ie, CD94/NKG2A) and function in developing human NK cells...
  4. ncbi request reprint Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma
    M Tomblyn
    Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 40:111-8. 2007
    ..The poor clinical outcome of patients with difficult mobilization using either method identifies them as a high-risk group who might benefit from alternative therapies...
  5. pmc Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:282-9. 2008
    ..A careful review of existing comorbidities is necessary when considering older patients for HCT...
  6. ncbi request reprint The biology of natural killer cells in cancer, infection, and pregnancy
    J S Miller
    Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minn 55455, USA
    Exp Hematol 29:1157-68. 2001
    ..The purpose of this review is to provide an update on NK cell function, ontogeny, and biology in order to better understand the role of NK cells in health and disease...
  7. ncbi request reprint Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2
    J S Miller
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Blood 98:705-13. 2001
    ..Blood. 2001;98:705-713)..
  8. ncbi request reprint Biology of natural killer cells in cancer and infection
    Jeffrey S Miller
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Box 806, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Cancer Invest 20:405-19. 2002
    ..Understanding NK cell function and homing may lead to novel therapeutic strategies for the treatment of human disease...
  9. ncbi request reprint Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells
    J S Miller
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 93:96-106. 1999
    ..This study provides new insights into the role of the microenvironment niche, which governs the earliest events in lymphoid development...
  10. ncbi request reprint Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor
    J S Miller
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis 55455, USA
    J Immunol 162:7376-82. 1999
    ..These studies demonstrate that NK proliferation is regulated through purine receptors by adenine nucleotides, which may play a role in decreased NK cell activity. The response to adenine nucleotides is lineage-specific...
  11. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Exp Hematol 28:96-103. 2000
    ..75 x 10(6) IU/m(2)/day. Fifteen women with stage IIIA/B or metastatic breast cancer underwent G-CSF mobilization alone and served as a control group...
  12. ncbi request reprint Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors
    S M Davies
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Am J Med 110:339-46. 2001
    ....
  13. pmc High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
    J R Long-Boyle
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 46:20-6. 2011
    ..5 μg h/mL had 4.56 greater risk of TRM and significantly lower OS. These data suggest that clinical strategies are needed to optimize dosing of fludarabine to prevent overexposure and toxicity in HCT...
  14. ncbi request reprint Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells
    C M Verfaillie
    Department of Medicine, Stem Cell Biology Program, Bone Marrow Transplantation Program, and Department of Laboratory Medicine at the University of Minnesota, Minneapolis, MN, USA
    Blood 92:1820-31. 1998
    ....
  15. pmc Factors predicting single-unit predominance after double umbilical cord blood transplantation
    P Ramirez
    Department of Medicine, University of Minnesota, Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 47:799-803. 2012
    ..4; P=0.05) were independent factors associated with unit predominance. Taken together, these findings suggest that immune reactivity has a role in unit predominance, and should be considered during graft selection and graft manipulation...
  16. ncbi request reprint T-cell factor-1 expression during human natural killer cell development and in circulating CD56(+) bright natural killer cells
    A A Toor
    Department of Medicine, University of Minnesota Cancer Center, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Exp Hematol 29:499-506. 2001
    ....
  17. pmc The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations
    Hongbo Wang
    Department of Pediatrics, Cancer Center, University of Minnesota, Minneapolis, USA
    Blood 110:1530-9. 2007
    ..Collectively, these studies show that CSA influences NK-cell function and phenotype, which may have important implications for graft-versus-leukemia effects...
  18. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
    ..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care...
  19. pmc Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation
    R Romee
    Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 48:1046-9. 2013
    ..Whereas ABO-compatible donors are preferred in recipients of URD-HCT, ABO compatibility generally need not be considered in recipients of UCB-HCT. ..
  20. ncbi request reprint Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
    L J Burns
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Exp Hematol 28:352. 2000
    ....
  21. ncbi request reprint Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units
    C G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:935-40. 2009
    ..Survival was 47% at 1 year. Despite safety of administration, IBMI of one of two UCB units did not shorten the time to neutrophil engraftment and offers no advantage over conventional double unit transplantation...
  22. doi request reprint Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma
    V Bachanova
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:237-44. 2009
    ....
  23. pmc KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation
    Sarah Cooley
    Division of Hematology Oncology and Transplantation, University of Minnesota Cancer Center, University of Minnesota, National Marrow Donor Program, MMC 806, Harvard St at E River Rd, Minneapolis, MN 55455, USA
    Blood 106:4370-6. 2005
    ..These results support the notion that T cells in the graft affect NK cell reconstitution in vivo. Understanding these mechanisms may result in strategies to improve clinical outcomes from unrelated HCT...
  24. pmc A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature
    Sarah Cooley
    Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis 55455, USA
    Blood 110:578-86. 2007
    ..These findings have implications for the function of NK cells reconstituting after transplantation and support a model for in vivo development in which CD56(bright) cells precede CD56(dim) cells...
  25. doi request reprint Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity
    Bryan A Whitson
    Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
    Ann Thorac Surg 86:1735-44. 2008
    ..Specifically, we assessed the cytotoxic capacity of peripheral blood mononuclear cells (PBMCs) of patients undergoing lobectomy for non-small-cell lung cancer by either VATS or thoracotomy...
  26. ncbi request reprint Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis
    Catherine M Flynn
    Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Hematol 82:867-72. 2007
    ..Advances in GVHD management and new approaches for relapsed or refractory disease are necessary to improve these outcomes...
  27. pmc A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity
    Gong Yun
    Division of Adult Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, MMC 806, Harvard Street at East River Road, Minneapolis, MN 55455, USA, and Anthony Nolan Research Institute, Royal Free Hospital, London, UK
    Clin Immunol 123:272-80. 2007
    ..Pyrosequencing is sensitive, specific, high-throughput, inexpensive, and can rapidly screen KIR-ligand status to evaluate potential alloreactive NK cell or transplant donors...
  28. pmc Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-like RNA in human NK cells
    Frank Cichocki
    Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    J Immunol 185:2009-12. 2010
    ....
  29. ncbi request reprint Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
    M Markova
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 39:193-9. 2007
    ..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens...
  30. ncbi request reprint Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity
    Petter S Woll
    Stem Cell Institute and Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    J Immunol 175:5095-103. 2005
    ..These cells may also provide a source for innovative cellular immune therapies...
  31. pmc Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 113:5628-34. 2009
    ..8; 95% CI, 1.0-3.1; P = .05). Our results do not support the selection of UCB units based on KIR-L status and suggest that KIR-L mismatching should be avoided in reduced intensity UCB transplantation...
  32. ncbi request reprint BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs)
    Elena G Chiorean
    Division of Hematology Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis, 55455, USA
    Blood 101:3527-33. 2003
    ..This is the first study to show that BCR/ABL, well known for its effects on the myeloid lineage, can alter the function of lymphoid cells, which may be associated with the defect in innate immunity associated with CML progression...
  33. ncbi request reprint Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation
    Elena G Chiorean
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:171-7. 2004
    ....
  34. ncbi request reprint Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, and the Blood and Marrow Transplant Program, University of Minnesota, MN 55455, USA
    Bone Marrow Transplant 35:1133-40. 2005
    ..Allogeneic HCT may be suitable in younger patients, soon after diagnosis, and in those with chemosensitive disease...
  35. pmc Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15
    Valarie McCullar
    Division of Medical, University of Minnesota Cancer Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Exp Hematol 36:598-608. 2008
    ..Human natural killer (NK) cell maturation involves the orderly acquisition of NK cell receptors. Our aim was to understand how stromal interactions and cytokines are important in this developmental process...
  36. ncbi request reprint Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1065-72. 2006
    ..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL...
  37. pmc Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions
    Veronika Bachanova
    Division of Adult and Pediatric Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:183-94. 2009
    ..However, these NK cells are immature in their cytokine production profile, are hyporesponsive, and poorly acquire NK cell receptors involved in self-tolerance and effector function...
  38. doi request reprint Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma
    M S Henson
    Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA
    Vet Comp Oncol 9:95-105. 2011
    ....
  39. ncbi request reprint Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor
    Stella M Davies
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Blood 100:3825-7. 2002
    ..It is possible that there will be a benefit of NK cell alloreactivity if strategies of haploidentical transplantation are used: high stem cell doses, extensive T-cell depletion, and no postgrafting immune suppression...
  40. pmc Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
    Sarah Cooley
    University of Minnesota, Minneapolis, USA
    Blood 113:726-32. 2009
    ..KIR genotyping of prospective donors, in addition to HLA typing, should be performed to identify HLA-matched donors with B KIR haplotypes...
  41. pmc Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation
    Marcie Tomblyn
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 14:538-45. 2008
    ..Modifications to refine patient assignment to the preferred conditioning intensity and reduce relapse risks with NMA approaches are needed...
  42. doi request reprint Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells
    Bryan A Whitson
    Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Surg Obes Relat Dis 5:181-93. 2009
    ..We hypothesized that the open approach to Roux-en-Y gastric bypass (RYGB) has a more deleterious, negative, quantifiable effect on the peripheral blood mononuclear cells than does the MIS approach...
  43. doi request reprint Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma
    Arkadiusz Z Dudek
    Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware St SE, MMC 480, Minneapolis, MN 55455, USA
    Am J Clin Oncol 31:173-81. 2008
    ..To evaluate the safety and activity of large multivalent immunogen (LMI), prepared by immobilizing autologous tumor cell plasma membrane on 5-microm diameter silica beads, in patients with melanoma and renal cell carcinoma (RCC)...
  44. pmc Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells
    Keli L Hippen
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone, Blood and Marrow Transplantation, Minneapolis, USA
    Blood 112:2847-57. 2008
    ..These data offer a novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL...
  45. doi request reprint Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation
    Claudio G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:214-22. 2009
    ..Based on our data, we conclude that a nonmyeloablative conditioning regimen followed by UCB transplantation is an effective treatment for patients with advanced lymphoid malignancies who lack a suitable sibling donor...
  46. ncbi request reprint Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults
    Juliet N Barker
    The University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Br J Haematol 118:101-7. 2002
    ..Future efforts should focus on improving the outcome for older BMT recipients, especially those with diagnoses other than CML...
  47. pmc Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Blood 117:1061-70. 2011
    ..These results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGVHD. This study is registered at http://www.clinicaltrials.gov as NCT00602693...
  48. ncbi request reprint The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients
    Hikaru Nakajima
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    J Immunol 168:643-50. 2002
    ..This study provides the first evidence that BCR/ABL is responsible for the altered differentiation of NK cells and that the NK cell lineage can be involved with the malignant clone in advanced stage CML...
  49. pmc NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT:
    Jeffrey S Miller
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 16:565-86. 2010
    ..Optimal strategies to precisely balance immune responses to favor GVL without harmful graft-versus-host disease (GVHD) are needed to protect against relapse, treat persistent disease and improve disease-free survival after HSCT...
  50. doi request reprint In vitro development of human Killer-Immunoglobulin Receptor-positive NK cells
    Frank Cichocki
    University of Minnesota Cancer Center, Minneapolis, MN, USA
    Methods Mol Biol 612:15-26. 2010
    ..The necessary soluble factors and contact-dependent conditions for in vitro human NK cell development have been worked out in our laboratory over the past 16 years...
  51. pmc The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells
    Michael R Verneris
    Department of Paediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA
    Br J Haematol 147:185-91. 2009
    ..Activation and expansion protocols for UCB NK cells are briefly reviewed. Lastly, we outline the early use of UCB NK cells in clinical trials...
  52. pmc Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation
    Jill C Beck
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 16:215-22. 2010
    ..01) and lower OS (P=.02). Thus, although recipient CMV serostatus and CMV reactivation have little demonstrable impact on UCB transplant outcomes, the development of CMV disease remains a risk, associated with inferior outcomes...
  53. pmc Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units
    Michael R Verneris
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 114:4293-9. 2009
    ..This trial was registered at http://clinicaltrials.gov as NCT00309842...
  54. ncbi request reprint Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor
    Paul J Orchard
    Program in Blood and Marrow Transplantation, Department of Pediatrics, Institute of Human Genetics, University of Minnesota, Minneapolis, MN 55455, USA
    Hum Gene Ther 13:979-88. 2002
    ..3% vs. 23.5%). We conclude that a strategy based on activation of human T cells with anti-CD3/CD28 beads can result in sufficient transduction, expansion, and purification based on NGFR expression for clinical trials...
  55. ncbi request reprint FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function
    Wei Chen
    University of Minnesota Cancer Center, Minneapolis, Minnesota 5455, USA
    Biol Blood Marrow Transplant 11:23-34. 2005
    ..These findings suggest that FLT3-L mobilization of DC precursors followed by a specific DC stimulus such as CpG ODN may provide a novel strategy to manipulate antitumor immunity in patients after HCT...
  56. ncbi request reprint Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
    ..Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell-dose barrier that limits the use of UCB in many adults and adolescents...
  57. ncbi request reprint iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types
    Troy C Lund
    Department of Medicine, Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 670 CCRB, 425 East River Road, Minneapolis, MN 55455, USA
    J Proteome Res 6:644-53. 2007
    ..This is the first demonstration and verification using iTRAQ to screen for membrane-bound protein differences in human NK cells and represents a powerful new tool in the field of proteomics...
  58. ncbi request reprint Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
    Jeffrey S Miller
    Division Medical and Pediatric Hematology Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 105:3051-7. 2005
    ..These findings suggest that haploidentical NK cells can persist and expand in vivo and may have a role in the treatment of selected malignancies used alone or as an adjunct to HCT...
  59. ncbi request reprint Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs
    Stephen B Porter
    University of Minnesota Cancer Center and the Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 82:23-9. 2006
    ..This study examines the effects of the most commonly used graft-versus-host disease (GVHD) prophylactic drugs on inducing apoptosis and suppressor cell function of human umbilical cord blood (UCB) CD4+25+ Treg and CD4+25- cells...
  60. ncbi request reprint Allogeneic natural killer cells for refractory lymphoma
    Veronika Bachanova
    Blood and Marrow, Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Immunol Immunother 59:1739-44. 2010
    ..Cell therapy trials should incorporate novel strategies to limit Treg expansion...
  61. ncbi request reprint The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory
    David H McKenna
    Division of Minnesota Molecular and Cellular Therapeutics Facility, University of Minnesota, Saint Paul, MN 55108, USA
    Transfus Med Rev 19:217-28. 2005
    ..Here we provide an overview of the Minnesota Molecular and Cellular Therapeutics (MMCT) Facility, detailing our approach to the manufacture of novel therapeutics and highlighting current and future activities...
  62. ncbi request reprint Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study
    Tanya Repka
    Division of Hematology Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 9:2440-6. 2003
    ..75 x 10(6) IU/m(2)/day, s.c.) for 7 weeks and trastuzumab (4 mg/kg load and then 2 mg/kg weekly) for 6 weeks. Safety, in vitro immune responses, and clinical responses were assessed...
  63. ncbi request reprint Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience
    David H McKenna
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School, Minnesota 55108, USA
    Transfusion 47:520-8. 2007
    ..Herein is a report on the experience of clinical-scale, good manufacturing practices (GMPs) production of NK cells to treat advanced cancer...
  64. pmc Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis MN, USA
    Blood 110:3064-70. 2007
    ..01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients...
  65. pmc Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
    Jeffrey S Miller
    Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 110:2761-3. 2007
    ..This trial was registered at www.clinicaltrials.gov as no. NCT00303693 and www.cancer.gov/clinicaltrials as no. NCT00167180...
  66. ncbi request reprint Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
    Juliet N Barker
    Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Blood 102:1915-9. 2003
    ..These data demonstrate that 0-2 antigen mismatched UCB is sufficient to engraft most adults after reduced-intensity conditioning and is associated with a low incidence of severe acute GVHD...
  67. ncbi request reprint Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)
    Mukta Arora
    Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:1145-52. 2007
    ..In addition, progressive onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM...
  68. pmc Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease
    K L Hippen
    Department of Pediatrics, Division of Hematology Oncology and Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, USA
    Am J Transplant 11:1148-57. 2011
    ..Most importantly, Rapa/TGFß iTregs suppress disease in a xenogeneic model of GVHD. This study opens the door for iTreg cellular therapy for human diseases...
  69. ncbi request reprint The biology of natural killer cells and implications for therapy of human disease
    E G Chiorean
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    J Hematother Stem Cell Res 10:451-63. 2001
    ..These and other novel strategies may prove to be attractive and effective immunotherapeutic tools to manipulate NK cells to fight human disease...
  70. pmc Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
    Sarah Cooley
    Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 116:2411-9. 2010
    ..Adopting this practice could result in superior disease-free survival for patients with AML...
  71. ncbi request reprint Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma
    Mukta Arora
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:395-404. 2004
    ..Two cycles of priming chemotherapy plus autologous transplantation yields survival rates similar to those in published reports, including those using tandem transplantation...
  72. ncbi request reprint First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer
    Arkadiusz Z Dudek
    University of Minnesota Cancer Center, Minneapolis, Minnesota and 3M Pharmaceuticals, St Paul, Minnesota 55455, USA
    Clin Cancer Res 13:7119-25. 2007
    ..Our goal was to define the tolerated dose, pharmacokinetics, pharmacodynamics, and immunologic effects of 852A in humans...
  73. doi request reprint Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML
    C Ustun
    1 Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA 2 Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 48:1415-20. 2013
    ..A strict morphologic and clinical lab flow cytometric definition of CR predicts outcomes after RIC allo-HCT, and therefore is critical to achieve at transplantation. ..
  74. ncbi request reprint IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
    L J Burns
    Blood and Marrow Transplant Program and Cancer Center, University of Minnesota, Mayo Mail Code 286, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 32:177-86. 2003
    ..With this dose and schedule of administration of IL-2, no improvement in patient disease outcomes was noted. Alternative strategies will be needed to exploit the immunotherapeutic potential of IL-2-activated NK cells...
  75. ncbi request reprint Novel therapies for chronic myelogenous leukemia
    B N Jahagirdar
    Stem Cell Institute, Division of Hematology-Oncology and Transplantation, University of Minnesota, Minneapolis, Minn 55455, USA
    Exp Hematol 29:543-56. 2001
    ..We have systematically reviewed each of these novel therapeutic approaches in this article...
  76. pmc Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade
    Robert Godal
    Division of Adult Hematology, Oncology and Transplantation, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 16:612-21. 2010
    ..Thus strategies to interrupt NKG2A and LIR-1 in combination with anti-KIR blockade hold promise for exploiting NK cell therapy in acute leukemias...
  77. pmc Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional
    Qin Tang
    Department of Pediatrics, Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    J Immunol 181:4507-15. 2008
    ..These results demonstrate differences between UCB and PB T cells regarding NCR expression and function. Such findings challenge the concept that NCRs are NK cell specific...
  78. ncbi request reprint A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I
    Deepali Sachdev
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 63:627-35. 2003
    ..These results indicate that such chimeric single-chain antibodies against IGF1R have future potential in breast cancer therapy by causing down-regulation of receptor...
  79. ncbi request reprint Liver and circulating NK1.1(+)CD3(-) cells are increased in infection with attenuated Salmonella typhimurium and are associated with reduced tumor in murine liver cancer
    B A Feltis
    Department of Surgery, University of Minnesota, Minneapolis 55455, USA
    J Surg Res 107:101-7. 2002
    ..1(+)CD3(-) lymphocytes compared to mice treated with saline (P < 0.01). These data suggest that attenuated S. typhimurium may have an application as an anti-tumor agent...
  80. pmc The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element
    Frank Cichocki
    Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 113:3245-53. 2009
    ..This finding provides a direct link between NK-cell activation signals and KIR expression required for acquisition of effector function during NK-cell education...
  81. ncbi request reprint Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
    Melissa A Geller
    Department of Obstetrics, Gynecology and Women s Health, University of Minnesota, MMC 395 420 Delaware St SE, Minneapolis, MN, 55455, USA
    Cancer Immunol Immunother 59:1877-84. 2010
    ..Secondary objectives included assessment of safety and immune system activation...
  82. ncbi request reprint Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
    Kevin S Gorski
    3M Pharmaceuticals, Department of Pharmacology, 3M Center, 270 2S 06, St Paul, MN 55144, USA
    Int Immunol 18:1115-26. 2006
    ..We conclude that IRMs can modulate NK-cell function both in vitro and in vivo and that distinct indirect pathways control human NK-cell activation by TLR-7 and TLR-8 agonists...
  83. pmc Use of natural killer cells as immunotherapy for leukaemia
    Bartosz Grzywacz
    Division of Blood and Marrow Transplantation, University of Minnesota, MN, USA
    Best Pract Res Clin Haematol 21:467-83. 2008
    ..Future modifications to improve NK cell adoptive immunotherapy by means of increasing target recognition and reducing inhibitory signalling are being explored...
  84. ncbi request reprint The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry
    Sherif S Farag
    The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:876-84. 2006
    ..There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing...
  85. ncbi request reprint Epigenetic control of highly homologous killer Ig-like receptor gene alleles
    Huei Wei Chan
    Department of Pathology and Laboratory Medicine, University of Kentucky, KY 40536, USA
    J Immunol 175:5966-74. 2005
    ..Our findings suggest that KIR transcription is primarily controlled by DNA methylation...